JAKi appear to be an effective and safety therapy in refractory GCA to cDMARDs and/or bDMARDs. Abs 0464 #ACR22 @RheumNow
JAKINIB in Refractory Giant Cell Arteritis. National Multicenter Study of 15 Cases and Literature Review - ACR Meeting Abstracts


